201 related articles for article (PubMed ID: 33968682)
1. Serum HER2 levels predict treatment efficacy and prognosis in patients with HER2-positive breast cancer undergoing neoadjuvant treatment.
Zuo WJ; He M; Zheng H; Liu Y; Liu XY; Jiang YZ; Wang ZH; Lu RQ; Shao ZM
Gland Surg; 2021 Apr; 10(4):1300-1314. PubMed ID: 33968682
[TBL] [Abstract][Full Text] [Related]
2. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.
Moreno-Aspitia A; Hillman DW; Dyar SH; Tenner KS; Gralow J; Kaufman PA; Davidson NE; Lafky JM; Reinholz MM; Lingle WL; Kutteh LA; Carney WP; Dueck AC; Perez EA
Cancer; 2013 Aug; 119(15):2675-82. PubMed ID: 23744760
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.
Witzel I; Loibl S; von Minckwitz G; Eidtmann H; Fehm T; Khandan F; Schmatloch S; Hauschild M; Bischoff J; Fasching PA; Mau C; Schem C; Rack B; Meinhold-Heerlein I; Liedtke C; Karn T; Huober J; Zu Eulenburg C; Issa-Nummer Y; Untch M; Müller V
Br J Cancer; 2012 Sep; 107(6):956-60. PubMed ID: 22892393
[TBL] [Abstract][Full Text] [Related]
4. The Significance of Serum HER2 Levels at Diagnosis on Intrinsic Subtype-Specific Outcome of Operable Breast Cancer Patients.
Lee MH; Jung SY; Kang SH; Song EJ; Park IH; Kong SY; Kwon YM; Lee KS; Kang HS; Lee ES
PLoS One; 2016; 11(10):e0163370. PubMed ID: 27706242
[TBL] [Abstract][Full Text] [Related]
5. Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.
Witzel I; Loibl S; von Minckwitz G; Mundhenke C; Huober J; Hanusch C; Henschen S; Hauschild M; Lantzsch T; Tesch H; Latos K; Just M; Hilfrich J; Barinoff J; Eulenburg CZ; Roller M; Untch M; Müller V
Breast Cancer Res Treat; 2010 Sep; 123(2):437-45. PubMed ID: 20623180
[TBL] [Abstract][Full Text] [Related]
6. Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients.
Wang S; Chen Y; Li W; Hao C; Zhang L; Zhao W; Shi Y; Tong Z
Breast Cancer (Dove Med Press); 2024; 16():163-179. PubMed ID: 38585222
[TBL] [Abstract][Full Text] [Related]
7. A multicenter study on efficacy of dual-target neoadjuvant therapy for HER2-positive breast cancer and a consistent analysis of efficacy evaluation of neoadjuvant therapy by Miller-Payne and RCB pathological evaluation systems (CSBrS-026).
Xiang H; Xin L; Ye J; Xu L; Zhang H; Zhang S; Liu Y
Chin J Cancer Res; 2023 Dec; 35(6):702-712. PubMed ID: 38204446
[TBL] [Abstract][Full Text] [Related]
8. Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab.
Wakatsuki T; Ishizuka N; Hironaka S; Minashi K; Kadowaki S; Goto M; Shoji H; Hirano H; Nakayama I; Osumi H; Ogura M; Chin K; Yamaguchi K; Takahari D
Int J Clin Oncol; 2024 Jun; 29(6):801-812. PubMed ID: 38589679
[TBL] [Abstract][Full Text] [Related]
9. Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.
Lee CK; Davies L; Gebski VJ; Lord SJ; Di Leo A; Johnston S; Geyer C; Cameron D; Press MF; Ellis C; Loi S; Marschner I; Simes J; de Souza P
J Clin Oncol; 2016 Mar; 34(9):936-44. PubMed ID: 26811533
[TBL] [Abstract][Full Text] [Related]
10. An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.
Perrier A; Boelle PY; Chrétien Y; Gligorov J; Lotz JP; Brault D; Comperat E; Lefèvre G; Boissan M
PLoS One; 2020; 15(1):e0227356. PubMed ID: 31910438
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
Yang X; Rao J; Yang W; Shui R
Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
[TBL] [Abstract][Full Text] [Related]
12. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
[TBL] [Abstract][Full Text] [Related]
13. Pilot Study on the Utility of Circulating HER2/Neu Levels in the Serum of Breast Cancer Patients.
Morgan S; Amemiya Y; Slodkowska E; Lu FI; Parra-Herran C; Nofech-Mozes S; Trudeau M; Olkhov-Mitsel E; Seth A; Hanna WM
Anticancer Res; 2019 Oct; 39(10):5345-5352. PubMed ID: 31570428
[TBL] [Abstract][Full Text] [Related]
14. Clinical Relevance of Tissue and Serum Human Epidermal Growth Factor Receptor 2 Expression in Patients With Esophageal Squamous Cell Carcinoma.
Nagata H; Tsujimoto H; Horiguchi H; Sugasawa H; Kouzu K; Itazaki Y; Ishibashi Y; Tsuchiya S; Sugihara T; Ito N; Harada M; Nomura S; Kishi Y; Ueno H
J Surg Res; 2022 Jan; 269():189-200. PubMed ID: 34583287
[TBL] [Abstract][Full Text] [Related]
15. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
[TBL] [Abstract][Full Text] [Related]
16. Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer.
Xie Y; Wu S; Zhang Y; Li J; Mo M; Shao Z; Liu G
Front Oncol; 2021; 11():686591. PubMed ID: 34168999
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
18. Molecular Subtype May Be More Associated With Prognosis and Chemotherapy Benefit Than Tumor Size in T1N0 Breast Cancer Patients: An Analysis of 2,168 Patients for Possible De-Escalation Treatment.
Zhu S; Li Y; Chen W; Fei X; Shen K; Chen X
Front Oncol; 2021; 11():636266. PubMed ID: 33680973
[TBL] [Abstract][Full Text] [Related]
19. Monitoring serum HER2 levels in breast cancer patients.
Tchou J; Lam L; Li YR; Edwards C; Ky B; Zhang H
Springerplus; 2015; 4():237. PubMed ID: 26069876
[TBL] [Abstract][Full Text] [Related]
20. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
